NCT04856189 2026-01-29
Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
University of California, Davis
Phase 1/2 Terminated
Clinical Trials
4 trialsNCT05985161 2025-11-26
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT02146833 2023-01-26
SHIP
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT02215161 2018-06-26
Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer
University of California, San Francisco
Phase 2 Terminated